肠道菌群与疾病相关性的研究进展

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (2): 243-247.

肠道菌群与疾病相关性的研究进展

张静, 王肖枭, 周怡, 王雪, 顾开明, 叶迎春^*

西南医科大学基础医学院病原生物学与医学免疫学实验室, 四川泸州 646000

收稿日期:2019-03-29 修回日期:2019-07-08 出版日期:2020-02-05 发布日期:2020-02-05
通讯作者: ^*351584908@qq.com
基金资助:
2017年国家级大学生创新创业训练项目(201710632045)

Advances in research on the relationship between intestinal flora and diseases

ZHANG Jing, WANG Xiao-xiao, ZHOU Yi, WANG Xue, GU Kai-ming, YE Ying-chun^*

Laboratory of Pathogenic Biology and Medical Immunology, School of Clinical Medicine Sciences, Southwest Medical University, Luzhou 646000, China

Received:2019-03-29 Revised:2019-07-08 Online:2020-02-05 Published:2020-02-05
Contact: ^*351584908@qq.com

摘要/Abstract

摘要： 肠道菌群数量庞大、种类繁多,其与宿主相互依存、相互影响。人体许多疾病的发生发展以及病情的转归都与肠道菌群有密不可分的联系。肠道微生物通过调节糖、脂质以及氨基酸等物质的代谢影响代谢疾病的发生与发展;肠道菌群紊乱还可促进炎性肠病与某些肠道肿瘤,补充益生菌可有助于这类疾病的治疗;此外,肠道菌群还与神经精神系统、心血管系统、泌尿系统等其他系统的疾病有着千丝万缕的联系。因此研究肠道菌群与疾病的相关性对疾病的预防与治疗,维护人类健康具有重大意义。

关键词: 肠道菌群, 代谢性疾病, 炎性肠病, 精神类疾病, 心血管疾病

Abstract: The quantity of intestinal flora is large and diverse, its interaction with the host. The intestinal flora is closely related to the development and the recovery of many human diseases. Intestinal microorganisms affect the occurrence and development of metabolic diseases by regulating the metabolism of substances such as sugar, lipids and amino acids; intestinal flora disorders can also promote inflammatory bowel disease and certain intestinal tumors, and supplementing probiotics can contribute to treat those diseases; In addition, the intestinal flora is closely related to other system such as the neuropsychiatric system, the cardiovascular system, and the urinary system. Therefore, studying the correlation between intestinal flora and disease is of great significance for the prevention and treatment of those diseases and the maintenance of human health.

Key words: intestinal flora, the metabolic diseases, inflammatory bowel disease, psychiatric diseases, cardiovascular diseases

中图分类号:

张静, 王肖枭, 周怡, 王雪, 顾开明, 叶迎春. 肠道菌群与疾病相关性的研究进展[J]. 基础医学与临床, 2020, 40(2): 243-247.

ZHANG Jing, WANG Xiao-xiao, ZHOU Yi, WANG Xue, GU Kai-ming, YE Ying-chun. Advances in research on the relationship between intestinal flora and diseases[J]. Basic & Clinical Medicine, 2020, 40(2): 243-247.

参考文献

[1]Fándriks L. Roles of the gut in the metabolic syndrome: an overview[J]. Intern Med, 2017, 281: 319-336.
[2]Li X, Watanabe K, Kimura I. Gut microbiota dysbiosis drives and implies novel therapeutic strategies for diabetes mellitus and related metabolic diseases[J]. Front Immunol, 2017, doi: 10.3389/fimmu.
[3]陈诚, 陆明, 夏娟. 肠道菌群与2型糖尿病关系的研究进展[J]. 医学综述, 2017, 23:3072-3076.
[4]Grasset E, Puel A, Charpentier J, et al. A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism[J]. Cell Metab, 2017, 25: 1075-1090.
[5]Kyriachenko Y, Falalyeyeva T, Korotkyi O, et al. Cross-talk between gut microbiota and antidiabetic drug action[J].World J Diabetes. 2019,10:154-168.
[6]Fandriks L. Roles of the gut in the metabolic syndrome: an overview[J]. J Intern Med, 2017, 281: 319-336.
[7]Louis S, Tappu RM, Damms-Machado A, et al. Characterization of the gut microbial community of obese patients following a weight-loss intervention using whole metage-nome shotgun sequencing[J]. PLoS One, 2016,11: e0149564. doi:10.1371/journal.pone.0149564.
[8]Nicolas S, Blasco-Baque V, Fournel A, et al. Transfer of dysbiotic gut microbiota has beneficial effects on host liver metabolism[J]. Mol Syst Biol, 2017,13: 921. doi: 10.15252/msb.20167356.
[9]Wang W, Chen L, Zhou R, et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease[J]. J Clin Microbiol, 2014. 52: 398-406.
[10]Goyal A, Yeh A, Bush BR, et al. Safety, clinical response, and microbiome findings following fecal micro-biota transplant in children with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2018, 24: 410-421.
[11]Liu SX, Li YH, Dai WK, et al. Fecal microbiota transplantation induces remission of infantile allergic colitis through gut microbiota re-establishment[J]. World J Gastroenterol, 2017, 23: 8570-8581.
[12]Schirmer M, Franzosa EA, Lloyd-Price J, et al. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome[J]. Nat Microbiol, 2018, 3:337-346.
[13]丁晓蕾, 张蓝方, 李明, 等. 肠道菌群与免疫的相关性研究[J]. 中国微生态学杂志, 2017, 29:971-974.
[14]Shen Y, Xu J, Li Z, et al. Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: a cross-sectional study[J]. Schizophr Res, 2018, 197: 470-477.
[15]Kelly JR, Borre Y, O' Brien C, et al. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat[J]. J Psychiatr Res, 2016. 82:109-118.
[16]Chen D,Yang X, Yang J, et al. Prebiotic effect of fructooligosaccharides from morinda officinalis on alzheimer's disease in rodent models by targeting the microbiota-gut-brain axis[J]. Front Aging Neurosci, 2017. doi: 10.3389/fnagi.2017.00403.
[17]Gong S, Lan T, Zeng L, et al. Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice[J]. J Hepatol, 2018, 69:51-59.
[18]Drago L. Probiotics and colon cancer[J]. Microor-ganisms, 2019, 7. doi: 10.3390/microorganisms7030066.
[19]Iyer C, Kosters A, Sethi G, et al. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling[J]. Cell Microbiol, 2008, 10:1442-1452.
[20]Steven E, Schuren FGJ, Nooijen IHG, et al. In vitro platform to study human gut microbiota induced drug metabolism and molecular transformations[J]. Drug Metab Pharmacokinet, 2018, 33:377-401.
[21]Miyamoto J, Kasubuchi M, Nakajima A, et al. The role of short-chain fatty acid on blood pressure regulation[J]. Curr Opin Nephrol Hypertens, 2016, 25: 379-383.
[22]Marques FZ, Nelson E, Chu PY, et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice[J]. Circulation, 2017, 135: 964-977.
[23]Cui X, Ye L, Li J, et al. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients[J]. Sci Rep, 2018, 8: 635. doi: 10.1038/s41598-017-18756-2.
[24]Ahmadmehrabi S, Tang WHW. Gut microbiome and its role in cardiovascular diseases[J]. Curr Opin Cardiol, 2017, 32: 761-766.
[25]Tang R, Jiang Y, Tan A, et al. 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones[J]. Urolithiasis, 2018, 46: 503-514.